CONMED (NYSE:CNMD) Releases FY 2026 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 4.480-4.600 for the period, compared to the consensus earnings per share estimate of 4.370. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Price Performance

Shares of NYSE:CNMD traded down $1.07 during trading on Wednesday, hitting $43.18. 762,515 shares of the company were exchanged, compared to its average volume of 558,600. CONMED has a 1-year low of $31.44 and a 1-year high of $56.63. The company has a market capitalization of $1.30 billion, a P/E ratio of 24.39, a price-to-earnings-growth ratio of 3.22 and a beta of 0.93. The company has a quick ratio of 1.04, a current ratio of 2.29 and a debt-to-equity ratio of 0.85. The business’s 50 day moving average is $36.76 and its 200-day moving average is $38.40.

CONMED (NYSE:CNMD) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.28. CONMED had a net margin of 4.00% and a return on equity of 13.84%. The business had revenue of $343.49 million during the quarter, compared to analyst estimates of $337.60 million. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. Equities analysts forecast that CONMED will post 4.38 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CNMD shares. BMO Capital Markets initiated coverage on shares of CONMED in a report on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 target price on the stock. Wall Street Zen raised CONMED from a “hold” rating to a “buy” rating in a report on Monday, July 20th. Weiss Ratings reissued a “sell (d)” rating on shares of CONMED in a research note on Thursday, June 4th. Bank of America reissued an “underperform” rating and issued a $40.00 price objective on shares of CONMED in a research note on Monday, June 29th. Finally, JPMorgan Chase & Co. cut their target price on CONMED from $43.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday, April 30th. Five investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $38.80.

Hedge Funds Weigh In On CONMED

Several institutional investors have recently modified their holdings of CNMD. AQR Capital Management LLC lifted its position in shares of CONMED by 19.9% during the 1st quarter. AQR Capital Management LLC now owns 14,199 shares of the company’s stock valued at $857,000 after buying an additional 2,357 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in CONMED by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock valued at $1,108,000 after acquiring an additional 800 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in CONMED by 5.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company’s stock valued at $4,993,000 after acquiring an additional 4,565 shares during the period. Intech Investment Management LLC lifted its holdings in CONMED by 34.6% during the first quarter. Intech Investment Management LLC now owns 22,505 shares of the company’s stock valued at $1,359,000 after purchasing an additional 5,780 shares during the last quarter. Finally, Creative Planning purchased a new stake in CONMED during the second quarter valued at about $310,000.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.